115 related articles for article (PubMed ID: 3841378)
1. Pharmacokinetics of methimazole in humans.
Hengstmann JH; Hohn H
Klin Wochenschr; 1985 Dec; 63(23):1212-7. PubMed ID: 3841378
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of methimazole in normal subjects and hyperthyroid patients.
Okamura Y; Shigemasa C; Tatsuhara T
Endocrinol Jpn; 1986 Oct; 33(5):605-15. PubMed ID: 3830069
[TBL] [Abstract][Full Text] [Related]
3. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.
Antonelli A; Ferrari SM; Corrado A; Ferrannini E; Fallahi P
Thyroid; 2013 Nov; 23(11):1461-9. PubMed ID: 23721189
[TBL] [Abstract][Full Text] [Related]
4. Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol.
Hallengren B; Nilsson OR; Karlberg BE; Melander A; Tegler L; Wåhlin-Boll E
Eur J Clin Pharmacol; 1982; 21(5):379-84. PubMed ID: 7075643
[TBL] [Abstract][Full Text] [Related]
5. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
[TBL] [Abstract][Full Text] [Related]
6. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic parameters of thiamazole in hyperthyroid patients responding rapidly and slowly to the treatment.
Syrenicz A; Gawrońska-Szklarz B; Wójcicki J; Czekalski S
Pol J Pharmacol Pharm; 1991; 43(3):207-12. PubMed ID: 1961693
[TBL] [Abstract][Full Text] [Related]
8. Impairment of prednisolone disposition in patients with Graves' disease taking methimazole.
Legler UF
J Clin Endocrinol Metab; 1988 Jan; 66(1):221-3. PubMed ID: 3335606
[TBL] [Abstract][Full Text] [Related]
9. A patient-specific treatment model for Graves' hyperthyroidism.
Pandiyan B; Merrill SJ; Di Bari F; Antonelli A; Benvenga S
Theor Biol Med Model; 2018 Jan; 15(1):1. PubMed ID: 29310665
[TBL] [Abstract][Full Text] [Related]
10. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
[TBL] [Abstract][Full Text] [Related]
11. [Results of thyrostatic therapy of hyperthyroidism in patients with Basedow's disease and disseminated autonomy].
Meng W; Meng S; Hampel R; Ventz M; Männchen E; Weber W; Streckenbach B
Dtsch Z Verdau Stoffwechselkr; 1987; 47(6):337-40. PubMed ID: 3129277
[TBL] [Abstract][Full Text] [Related]
12. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
[TBL] [Abstract][Full Text] [Related]
14. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
15. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
16. COMPUTED TOMOGRAPHIC CHARACTERISTICS OF THE THYROID GLANDS IN EIGHT HYPERTHYROID CATS PRE- AND POSTMETHIMAZOLE TREATMENT COMPARED WITH SEVEN EUTHYROID CATS.
Bush JL; Nemanic S; Gordon J; Bobe G
Vet Radiol Ultrasound; 2017 Mar; 58(2):176-185. PubMed ID: 27918152
[TBL] [Abstract][Full Text] [Related]
17. Plasma atrial natriuretic peptide, plasma renin activity and aldosterone during treatment of hyperthyroidism due to Graves' disease.
Shigematsu S; Iwasaki T; Aizawa T; Ishihara M; Shinoda T; Yamada T; Sato A; Takemura Y
Horm Metab Res; 1989 Sep; 21(9):514-8. PubMed ID: 2531114
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy.
Gianetti E; Russo L; Orlandi F; Chiovato L; Giusti M; Benvenga S; Moleti M; Vermiglio F; Macchia PE; Vitale M; Regalbuto C; Centanni M; Martino E; Vitti P; Tonacchera M
J Endocrinol Invest; 2015 Sep; 38(9):977-85. PubMed ID: 25840794
[TBL] [Abstract][Full Text] [Related]
19. Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial.
Bonnema SJ; Bennedbaek FN; Veje A; Marving J; Hegedüs L
J Clin Endocrinol Metab; 2006 Aug; 91(8):2946-51. PubMed ID: 16735487
[TBL] [Abstract][Full Text] [Related]
20. Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function.
Iglesias P; Acosta M; Sánchez R; Fernández-Reyes MJ; Mon C; Díez JJ
Clin Endocrinol (Oxf); 2005 Jul; 63(1):66-72. PubMed ID: 15963064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
